
    
      Patients who had no evidence of disease progression or toxicity while participating in study
      8400-401 (NCT02092909) will continue to receive IMO-8400 until disease progression, adverse
      event or the investigator deems the goals of extended treatment with IMO-8400 have been met.
    
  